What is Abogen?
Founded in 2012, Abogen is dedicated to pioneering the future of personalized medicine. The company's core mission revolves around developing novel alternatives to traditional blood draws for obtaining comprehensive genomic information. This innovative approach aims to revolutionize diagnostics and therapeutic strategies, positioning Abogen at the forefront of the rapidly evolving healthcare and biotechnology sectors. Their focus on advanced genomic analysis signifies a commitment to unlocking deeper biological insights for tailored medical interventions.
How much funding has Abogen raised?
Abogen has raised a total of $1.1B across 3 funding rounds:
Multiple Rounds
$1.1B
Series B (2021): $92M with participation from YF Capital, Ming Bioventures, SDIC Venture Capital, Qiming Venture Partners, LYFE Capital, GL Ventures, HighLight Capital, PICC Capital Investment Management, and TF Capital
Series C (2021): $700M led by Invesco Developing Markets Fund and Temasek
Unspecified (2021): $300M supported by 5Y Capital, Chimera Abu Dhabi, Mirae Asset Financial, Fortune Ocean, and SoftBank Group
Key Investors in Abogen
SDIC Venture Capital
SDIC Venture Capital is a venture capital management firm specializing in advanced manufacturing, electronic information, material energy, and biomedicine sectors. They aim to foster innovation and growth in these industries by investing in startups and enterprises.
Qiming Venture Partners
Qiming Venture Partners is a prominent venture capital firm focusing on technology, healthcare, and artificial intelligence. They support entrepreneurs by providing industry resources and strategic guidance to achieve significant growth.
LYFE Capital
LYFE Capital is a premier healthcare investment platform that focuses on investing in critical healthcare supply chain assets, specialized product platforms, and next-generation R&D services. They aim to scale high-potential businesses in the healthcare sector.
What's next for Abogen?
The substantial capital raised, particularly the recent strategic investment, signals a new phase of accelerated growth and development for Abogen. This financing is expected to fuel further research and development into their novel genomic information technologies, potentially expanding their market reach and solidifying their position as a leader in personalized medicine. The company is poised to leverage this backing to scale its operations, enhance its product pipeline, and pursue strategic partnerships that will drive innovation and market penetration in the global healthcare landscape.
See full Abogen company page
